Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development.

Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, Perou CM, Livingstone AS, Robbins DJ, Capobianco AJ, Pei XH.

Cancer Res. 2014 Nov 1;74(21):6161-72. doi: 10.1158/0008-5472.CAN-14-1119. Epub 2014 Sep 19.

PMID:
25239453
2.

Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status.

Sandhu R, Rein J, D'Arcy M, Herschkowitz JI, Hoadley KA, Troester MA.

Carcinogenesis. 2014 Nov;35(11):2567-75. doi: 10.1093/carcin/bgu175. Epub 2014 Aug 14.

PMID:
25123132
3.

Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts.

Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM.

Genome Biol. 2013 Nov 12;14(11):R125. doi: 10.1186/gb-2013-14-11-r125.

4.

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.

Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, Baker LA, Armstrong N, Cowley MJ, Naylor MJ, Ormandy CJ, Lakhani SR, Herschkowitz JI, Perou CM, Kaplan W, O'Toole SA, Swarbrick A.

Oncogene. 2014 Jul 24;33(30):3992-4002. doi: 10.1038/onc.2013.368. Epub 2013 Sep 23.

PMID:
24056965
5.

Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties.

Taube JH, Malouf GG, Lu E, Sphyris N, Vijay V, Ramachandran PP, Ueno KR, Gaur S, Nicoloso MS, Rossi S, Herschkowitz JI, Rosen JM, Issa JP, Calin GA, Chang JT, Mani SA.

Sci Rep. 2013;3:2687. doi: 10.1038/srep02687.

6.

Predicting drug responsiveness in human cancers using genetically engineered mice.

Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, Sharpless NE, Perou CM.

Clin Cancer Res. 2013 Sep 1;19(17):4889-99. doi: 10.1158/1078-0432.CCR-13-0522. Epub 2013 Jun 18.

7.

Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.

Knight JF, Lesurf R, Zhao H, Pinnaduwage D, Davis RR, Saleh SM, Zuo D, Naujokas MA, Chughtai N, Herschkowitz JI, Prat A, Mulligan AM, Muller WJ, Cardiff RD, Gregg JP, Andrulis IL, Hallett MT, Park M.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1301-10. doi: 10.1073/pnas.1210353110. Epub 2013 Mar 18.

8.

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA.

Cancer Res. 2013 Mar 15;73(6):1981-92. doi: 10.1158/0008-5472.CAN-12-2962. Epub 2013 Feb 1.

9.

Noncoding RNAs involved in mammary gland development and tumorigenesis: there's a long way to go.

Shore AN, Herschkowitz JI, Rosen JM.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):43-58. doi: 10.1007/s10911-012-9247-3. Epub 2012 Mar 9. Review.

10.

Mouse models of triple negative [basal-like/claudin low] breast cancer.

Herschkowitz JI, Lubet R.

Breast Dis. 2010;32(1-2):63-71. doi: 10.3233/BD-2010-0321. Review.

PMID:
21965308
11.

MicroRNAs add an additional layer to the complexity of cell signaling.

Herschkowitz JI, Fu X.

Sci Signal. 2011 Jul 26;4(184):jc5. doi: 10.1126/scisignal.2002182. Review.

PMID:
21868350
12.

Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.

Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. doi: 10.1073/pnas.1018862108. Epub 2011 Jun 1.

13.

RB1 and p53 at the crossroad of EMT and triple-negative breast cancer.

Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E.

Cell Cycle. 2011 May 15;10(10):1563-70. Epub 2011 May 15. Review.

14.

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo.

Meerbrey KL, Hu G, Kessler JD, Roarty K, Li MZ, Fang JE, Herschkowitz JI, Burrows AE, Ciccia A, Sun T, Schmitt EM, Bernardi RJ, Fu X, Bland CS, Cooper TA, Schiff R, Rosen JM, Westbrook TF, Elledge SJ.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3665-70. doi: 10.1073/pnas.1019736108. Epub 2011 Feb 9.

15.

MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements.

Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo A, Perou CM, Lanari C.

Breast Cancer Res Treat. 2011 Aug;129(1):49-67. doi: 10.1007/s10549-010-1185-4. Epub 2010 Oct 2.

PMID:
20890655
16.

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM.

Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2.

17.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132.

18.

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E.

J Clin Invest. 2010 Sep;120(9):3296-309. doi: 10.1172/JCI41490. Epub 2010 Aug 2.

19.

Small players with big roles: microRNAs as targets to inhibit breast cancer progression.

Greene SB, Herschkowitz JI, Rosen JM.

Curr Drug Targets. 2010 Sep;11(9):1059-73. Review.

20.

Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer.

Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM.

Cancer Res. 2010 Jun 15;70(12):4868-79. doi: 10.1158/0008-5472.CAN-09-4404. Epub 2010 May 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk